A phase I, randomized, double-blind, placebo-controlled, single-dose, sequential-group escalation, first in human, single-center study to evaluate the safety, tolerability, and pharmacokinetics parameters of ONO-4232 versus placebo in healthy volunteers
Latest Information Update: 29 Mar 2016
Price :
$35 *
At a glance
- Drugs ONO 4232 (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man
- Sponsors Ono Pharmaceutical
- 29 Mar 2016 New trial record
- 18 Mar 2016 Results (n=76) published in the Clinical Therapeutics.